JP2022516574A - 新規ペプチドとその使用 - Google Patents

新規ペプチドとその使用 Download PDF

Info

Publication number
JP2022516574A
JP2022516574A JP2021539599A JP2021539599A JP2022516574A JP 2022516574 A JP2022516574 A JP 2022516574A JP 2021539599 A JP2021539599 A JP 2021539599A JP 2021539599 A JP2021539599 A JP 2021539599A JP 2022516574 A JP2022516574 A JP 2022516574A
Authority
JP
Japan
Prior art keywords
amyloid
peptide
disease
peptides
attenuate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021539599A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022516574A5 (https=
Inventor
デウジ ナズニーン
Original Assignee
センナ バイオサイエンシーズ インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by センナ バイオサイエンシーズ インク． filed Critical センナ バイオサイエンシーズ インク．
Publication of JP2022516574A publication Critical patent/JP2022516574A/ja
Publication of JP2022516574A5 publication Critical patent/JP2022516574A5/ja
Priority to JP2024207280A priority Critical patent/JP2025041635A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2021539599A 2019-01-07 2020-01-06 新規ペプチドとその使用 Pending JP2022516574A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024207280A JP2025041635A (ja) 2019-01-07 2024-11-28 新規ペプチドとその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962789114P 2019-01-07 2019-01-07
US62/789,114 2019-01-07
PCT/US2020/012323 WO2020146236A1 (en) 2019-01-07 2020-01-06 Novel peptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024207280A Division JP2025041635A (ja) 2019-01-07 2024-11-28 新規ペプチドとその使用

Publications (2)

Publication Number Publication Date
JP2022516574A true JP2022516574A (ja) 2022-02-28
JP2022516574A5 JP2022516574A5 (https=) 2023-01-23

Family

ID=71520880

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021539599A Pending JP2022516574A (ja) 2019-01-07 2020-01-06 新規ペプチドとその使用
JP2024207280A Pending JP2025041635A (ja) 2019-01-07 2024-11-28 新規ペプチドとその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024207280A Pending JP2025041635A (ja) 2019-01-07 2024-11-28 新規ペプチドとその使用

Country Status (9)

Country Link
US (1) US20220064214A1 (https=)
EP (1) EP3908307A4 (https=)
JP (2) JP2022516574A (https=)
KR (1) KR20220004618A (https=)
CN (2) CN113853382A (https=)
AU (2) AU2020207203A1 (https=)
CA (1) CA3125552A1 (https=)
IL (1) IL284666A (https=)
WO (1) WO2020146236A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077740A1 (en) * 2001-03-05 2003-04-24 Schubert David R. Presenilin/Crk binding polypeptides (PCBP) and methods of use thereof
JP2012526557A (ja) * 2009-05-12 2012-11-01 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 神経変性障害およびアルツハイマー病を処置し、正常な記憶を改善するための方法および組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966848A (en) * 1988-02-08 1990-10-30 The General Hospital Corporation Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase
US5223421A (en) * 1989-10-25 1993-06-29 The General Hospital Corporation Identification of methionine Nα-acetyltransferase
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US6777388B1 (en) * 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
JP2013526518A (ja) * 2010-05-13 2013-06-24 ザ ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション Ｍｃｉおよびアルツハイマー病の処置
CN106456799B (zh) * 2014-06-03 2020-05-22 江苏佳瑞生物技术有限公司 肽-药物偶联物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077740A1 (en) * 2001-03-05 2003-04-24 Schubert David R. Presenilin/Crk binding polypeptides (PCBP) and methods of use thereof
JP2012526557A (ja) * 2009-05-12 2012-11-01 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 神経変性障害およびアルツハイマー病を処置し、正常な記憶を改善するための方法および組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUN, N., ET AL.: ""A servey of peptides with effective therapeutic potential in Alzheimer's disease rodent models or i", MINI-REVIEWS IN MEDICINAL CHEMISTRY, vol. 12, no. 5, JPN6023048873, 2012, pages 388 - 398, ISSN: 0005380050 *

Also Published As

Publication number Publication date
EP3908307A1 (en) 2021-11-17
CA3125552A1 (en) 2020-07-16
EP3908307A4 (en) 2022-10-12
CN114437173A (zh) 2022-05-06
IL284666A (en) 2021-08-31
CN113853382A (zh) 2021-12-28
JP2025041635A (ja) 2025-03-26
AU2026200229A1 (en) 2026-02-05
US20220064214A1 (en) 2022-03-03
AU2020207203A1 (en) 2021-08-19
KR20220004618A (ko) 2022-01-11
WO2020146236A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
JP5823954B2 (ja) Ｆｇｆ２１変異体及びその使用
US10213506B2 (en) Targeting immunotherapy for amyloidosis
CN107921085B (zh) 用于治疗衰老相关病症的方法和组合物
JP2021527656A (ja) プログラニュリンを含む融合タンパク質
JP2010506860A (ja) Ｐ−糖タンパク質機能を刺激するための化合物およびその使用
CN102459348A (zh) 用于将gdnf和bdnf递送至中枢神经系统的融合蛋白
KR20220130678A (ko) 프로그라눌린 변이체들
JP2013518119A (ja) プロミニン−１の血管新生促進フラグメントおよびその使用
JP2025163012A (ja) レトロインベルソペプチド
KR102569658B1 (ko) 컨쥬게이트 c1 에스테라제 억제제 및 그의 용도
JP2009519006A (ja) 改善された色素上皮由来因子変異体及びその使用
US20060205668A1 (en) Central nervous system damage
JP2022516574A (ja) 新規ペプチドとその使用
CA2621539C (en) Methods for treating immune mediated neurological diseases
WO2014061772A1 (ja) 新規ｎｋ３受容体アゴニスト
WO2020154363A1 (en) Engineered nucleobindin1-immunoglobulin fusion protein
WO2021123047A1 (en) Macrocyclic peptides
JPWO2015083816A1 (ja) 新規ｎｋ３受容体アゴニスト
HK40054557A (en) Retro-inverso peptides
JP2022544401A (ja) Ｔｇｆ－ベータトラップ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240730